在实验性质瘤中对ATR抑制反应的功能指导修饰剂
Bianca Walter1,2, Sophie Hirsch1,2, Laurence Kuhlburger1,2,3,4
1Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, 72076, Tübingen, Germany.
Journal of experimental & clinical cancer research : CR
|March 13, 2024
概括
用ATAXIA telangiectasia和Rad3相关的 (ATR) 抑制向DNA损伤反应 (DDR) 对质母细胞瘤治疗有希望. 发现了涉及ATR抑制的新组合疗法,以提高抗质瘤的疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 通过管理DNA修复和细胞循环停止,DNA损伤反应 (DDR) 网络对于预防癌症至关重要.
- 质母细胞瘤中DDR通路的失调有助于治疗耐药性,强调DDR向作为治疗策略.
- ATAXIA telangiectasia和Rad3相关的 (ATR) 抑制 (ATRi) 是作为一种潜在的抗质瘤疗法被探索的.
研究的目的:
- 为了研究ATR抑制 (ATRi) 作为单一治疗和组合治疗实验性质瘤的疗效.
- 确定可以增强ATRi在质瘤中的治疗效果的分子标.
- 验证用于临床前和临床开发的新型组合策略.
主要方法:
- 用细胞毒性测定,RNA测序和DigiWest蛋白质分析来评估ATRi的有效性和分子变化.
- 全基因组的CRISPR/Cas9屏幕识别了调节ATRi反应的分子标.
- 在各种质瘤模型 (体外,体外,体内) 中使用功能测试,shRNA和药物库进行了验证.
主要成果:
- 单一治疗ATRi显示出抗质瘤活性,并改变了质瘤细胞中的分子格局.
- 通过CRISPR/Cas9选,成功地确定了增强ATRi治疗效果的分子标.
- 经过验证的标和组合疗法在体外,体外和体内模型中显示出有效性.
结论:
- 该研究确定了用于质母细胞瘤的ATRi的新型组合疗法.
- 这些发现为未来的临床前研究和针对质瘤的早期临床试验提供了基础.
相关概念视频
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
01:28Drugs Acting on Autonomic Ganglia: Blockers
1.0K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.0K